Cargando…
Neutralizing antiviral antibody responses
Neutralizing antibodies are evolutionarily important effectors of immunity against viruses. Their evaluation has revealed a number of basic insights into specificity, rules of reactivity (tolerance), and memory—namely, (1) Specificity of neutralizing antibodies is defined by their capacity to distin...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7130890/ https://www.ncbi.nlm.nih.gov/pubmed/11680006 http://dx.doi.org/10.1016/S0065-2776(01)79001-3 |
_version_ | 1783517113506332672 |
---|---|
author | Zinkernagel, Rolf M. Lamarre, Alain Ciurea, Adrian Hunziker, Lukas Ochsenbein, Adrian F. Mccoy, Kathy D. Fehr, Thomas Bachmann, Martin F. Kalinke, Ulrich Hengartner, Hans |
author_facet | Zinkernagel, Rolf M. Lamarre, Alain Ciurea, Adrian Hunziker, Lukas Ochsenbein, Adrian F. Mccoy, Kathy D. Fehr, Thomas Bachmann, Martin F. Kalinke, Ulrich Hengartner, Hans |
author_sort | Zinkernagel, Rolf M. |
collection | PubMed |
description | Neutralizing antibodies are evolutionarily important effectors of immunity against viruses. Their evaluation has revealed a number of basic insights into specificity, rules of reactivity (tolerance), and memory—namely, (1) Specificity of neutralizing antibodies is defined by their capacity to distinguish between virus serotypes; (2) B cell reactivity is determined by antigen structure, concentration, and time of availability in secondary lymphoid organs; and (3) B cell memory is provided by elevated protective antibody titers in serum that are depending on antigen stimulation. These perhaps slightly overstated rules are simple, correlate with in vivo evidence as well as clinical observations, and appear to largely demystify many speculations about antibodies and B cell physiology. The chapter also considers successful vaccines and compares them with those infectious diseases where efficient protective vaccines are lacking, it is striking to note that all successful vaccines induce high levels of neutralizing antibodies (nAbs) that are both necessary and sufficient to protect the host from disease. Successful vaccination against infectious diseases such as tuberculosis, leprosy, or HIV would require induction of additional long-lasting T cell responses to control infection. |
format | Online Article Text |
id | pubmed-7130890 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2001 |
publisher | Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71308902020-04-08 Neutralizing antiviral antibody responses Zinkernagel, Rolf M. Lamarre, Alain Ciurea, Adrian Hunziker, Lukas Ochsenbein, Adrian F. Mccoy, Kathy D. Fehr, Thomas Bachmann, Martin F. Kalinke, Ulrich Hengartner, Hans Adv Immunol Article Neutralizing antibodies are evolutionarily important effectors of immunity against viruses. Their evaluation has revealed a number of basic insights into specificity, rules of reactivity (tolerance), and memory—namely, (1) Specificity of neutralizing antibodies is defined by their capacity to distinguish between virus serotypes; (2) B cell reactivity is determined by antigen structure, concentration, and time of availability in secondary lymphoid organs; and (3) B cell memory is provided by elevated protective antibody titers in serum that are depending on antigen stimulation. These perhaps slightly overstated rules are simple, correlate with in vivo evidence as well as clinical observations, and appear to largely demystify many speculations about antibodies and B cell physiology. The chapter also considers successful vaccines and compares them with those infectious diseases where efficient protective vaccines are lacking, it is striking to note that all successful vaccines induce high levels of neutralizing antibodies (nAbs) that are both necessary and sufficient to protect the host from disease. Successful vaccination against infectious diseases such as tuberculosis, leprosy, or HIV would require induction of additional long-lasting T cell responses to control infection. Published by Elsevier Inc. 2001 2004-01-07 /pmc/articles/PMC7130890/ /pubmed/11680006 http://dx.doi.org/10.1016/S0065-2776(01)79001-3 Text en Copyright © 2001 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Zinkernagel, Rolf M. Lamarre, Alain Ciurea, Adrian Hunziker, Lukas Ochsenbein, Adrian F. Mccoy, Kathy D. Fehr, Thomas Bachmann, Martin F. Kalinke, Ulrich Hengartner, Hans Neutralizing antiviral antibody responses |
title | Neutralizing antiviral antibody responses |
title_full | Neutralizing antiviral antibody responses |
title_fullStr | Neutralizing antiviral antibody responses |
title_full_unstemmed | Neutralizing antiviral antibody responses |
title_short | Neutralizing antiviral antibody responses |
title_sort | neutralizing antiviral antibody responses |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7130890/ https://www.ncbi.nlm.nih.gov/pubmed/11680006 http://dx.doi.org/10.1016/S0065-2776(01)79001-3 |
work_keys_str_mv | AT zinkernagelrolfm neutralizingantiviralantibodyresponses AT lamarrealain neutralizingantiviralantibodyresponses AT ciureaadrian neutralizingantiviralantibodyresponses AT hunzikerlukas neutralizingantiviralantibodyresponses AT ochsenbeinadrianf neutralizingantiviralantibodyresponses AT mccoykathyd neutralizingantiviralantibodyresponses AT fehrthomas neutralizingantiviralantibodyresponses AT bachmannmartinf neutralizingantiviralantibodyresponses AT kalinkeulrich neutralizingantiviralantibodyresponses AT hengartnerhans neutralizingantiviralantibodyresponses |